Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Delving into the POLARIX trial data on Roche's Polivy in patients with Diffuse Large B Cell Lymphoma (DLBCL).

Ticker(s): RHHBY

Who's the expert?

Institution: University of Texas Southwestern Medical Center

Hematopathologist affiliated with UT Southwestern Medical Center
Research interests include atherosclerosis, thrombosis, vascular biology, lipid metabolism, GVHD, molecular pathogenesis of lymphoma and leukemia, tumor immunology, viral infections and cancergenesis
Published over 90 peer reviewed papers, 120 abstracts and 11 book chapters
Manages 45 patients with PNH and has prescribed Epaveli

Interview Goal

to discuss the standard of care and the potential of Roche/Genentech's antibody-drug conjugate Polivy (polatuzumab vedotin-piiq), combined with the cancer regimen R-CHP, which was recently approved for the additional indication of first-line DLBCL.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.